MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:28Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Proton pump inhibitors]]
			[[Category:Antisecretory agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #10

2026-05-23T03:29:42Z

parser-claude batch MedTemplate pre-fill, Top 300 #10

New page

{{MedTemplate
| generic = Omeprazole
| brand = Prilosec, Losec, Zegerid
| structure =
| classes = [[:Category:Proton_pump_inhibitors|Proton pump inhibitor (PPI)]], [[:Category:Antisecretory_agents|Gastric acid suppressant]]
| uses = <vote slug="gerd-use">GERD</vote>, <vote slug="pud-use">Peptic ulcer disease</vote>, <vote slug="h-pylori-use">H. pylori eradication (combination)</vote>, <vote slug="zollinger-ellison-use">Zollinger-Ellison syndrome</vote>
| starting_dose = 20 mg PO once daily 30-60 minutes before breakfast
| preparations = 10, 20, 40 mg delayed-release capsules and tablets; 2 mg/mL oral suspension; immediate-release combo with sodium bicarbonate (Zegerid)
| fda_max = 40 mg/d typical; up to 360 mg/d for Zollinger-Ellison
| pill_id =
| routes = Oral, IV
| onset = Symptom relief 1-4 days; full acid suppression after 3-5 days of dosing
| duration = 24-72 hours per dose (irreversible enzyme binding; effect outlasts plasma exposure)
| halflife = 0.5-1.5 hours (plasma); pharmacodynamic effect persists 24+ hours<ref name="prilosec-label">FDA Prescribing Information, Prilosec (omeprazole), AstraZeneca, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf</ref>
| bioavailability = 30-40% (oral; increases with repeated dosing as gastric pH rises)<ref name="prilosec-label" />
| pregnancy = Widely used in pregnancy; meta-analyses do not show increased malformation risk.{{citation needed}}
| legal = OTC (20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US
| mechanism = <vote slug="omeprazole-mech-claim">Omeprazole is a prodrug activated in the acidic environment of parietal-cell secretory canaliculi to a sulfenamide that covalently binds the H+/K+ ATPase, irreversibly blocking the final common step of gastric acid secretion.</vote> Recovery of acid output requires synthesis of new pump enzyme. CYP2C19 substrate; PGx genotype substantially affects exposure and efficacy<ref name="cpic-ppi-cyp2c19">CPIC Guideline for CYP2C19 and Proton Pump Inhibitors, 2020. https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/</ref>.
}}

== References ==
<references />

Omeprazole - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #10